Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 150


Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma.

Xu L, Mohammad KS, Wu H, Crean C, Poteat B, Cheng Y, Cardoso AA, Machal C, Hanenberg H, Abonour R, Kacena MA, Chirgwin J, Suvannasankha A, Srour EF.

Cancer Res. 2016 Dec 1;76(23):6901-6910. Epub 2016 Sep 7.


Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.

Colleoni M, Gray KP, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi EA, Gomez HL, Linderholm BK, Puglisi F, Tondini C, Kralidis E, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber RD, Regan MM, Coates AS, Price KN, Viale G, Goldhirsch A.

J Clin Oncol. 2016 Oct 1;34(28):3400-8. doi: 10.1200/JCO.2015.65.6595. Epub 2016 Jun 20.


Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.

Chirgwin JH, Giobbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, Gelber RD, Goldhirsch A, Smith I, Rabaglio M, Forbes JF, Neven P, Láng I, Colleoni M, Thürlimann B.

J Clin Oncol. 2016 Jul 20;34(21):2452-9. doi: 10.1200/JCO.2015.63.8619. Epub 2016 May 23.


Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.

Delgado-Calle J, Anderson J, Cregor MD, Hiasa M, Chirgwin JM, Carlesso N, Yoneda T, Mohammad KS, Plotkin LI, Roodman GD, Bellido T.

Cancer Res. 2016 Mar 1;76(5):1089-100. doi: 10.1158/0008-5472.CAN-15-1703. Epub 2016 Feb 1.


Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options.

Lombard JM, Zdenkowski N, Wells K, Beckmore C, Reaby L, Forbes JF, Chirgwin J.

Support Care Cancer. 2016 May;24(5):2139-2146. doi: 10.1007/s00520-015-3001-5. Epub 2015 Nov 10.


Unmet needs and depression among carers of people newly diagnosed with cancer.

Heckel L, Fennell KM, Reynolds J, Osborne RH, Chirgwin J, Botti M, Ashley DM, Livingston PM.

Eur J Cancer. 2015 Sep;51(14):2049-57. doi: 10.1016/j.ejca.2015.06.129. Epub 2015 Jul 21.


The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone.

Fournier PG, Juárez P, Jiang G, Clines GA, Niewolna M, Kim HS, Walton HW, Peng XH, Liu Y, Mohammad KS, Wells CD, Chirgwin JM, Guise TA.

Cancer Cell. 2015 Jun 8;27(6):809-21. doi: 10.1016/j.ccell.2015.04.009. Epub 2015 May 14.


FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells.

Suvannasankha A, Tompkins DR, Edwards DF, Petyaykina KV, Crean CD, Fournier PG, Parker JM, Sandusky GE, Ichikawa S, Imel EA, Chirgwin JM.

Oncotarget. 2015 Aug 14;6(23):19647-60.


Role of bone-anabolic agents in the treatment of breast cancer bone metastases.

Suvannasankha A, Chirgwin JM.

Breast Cancer Res. 2014;16(6):484. Review.


Development of a conceptual model of cancer caregiver health literacy.

Yuen EY, Dodson S, Batterham RW, Knight T, Chirgwin J, Livingston PM.

Eur J Cancer Care (Engl). 2016 Mar;25(2):294-306. doi: 10.1111/ecc.12284. Epub 2015 Jan 29.


Adjuvant ovarian suppression in premenopausal breast cancer.

Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD; SOFT Investigators; International Breast Cancer Study Group.

N Engl J Med. 2015 Jan 29;372(5):436-46. doi: 10.1056/NEJMoa1412379. Epub 2014 Dec 11.


Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis.

Siclari VA, Mohammad KS, Tompkins DR, Davis H, McKenna CR, Peng X, Wessner LL, Niewolna M, Guise TA, Suvannasankha A, Chirgwin JM.

Breast Cancer Res. 2014 Dec 2;16(6):458. doi: 10.1186/s13058-014-0458-y.


A prospective cohort study of the effects of adjuvant breast cancer chemotherapy on taste function, food liking, appetite and associated nutritional outcomes.

Boltong A, Aranda S, Keast R, Wynne R, Francis PA, Chirgwin J, Gough K.

PLoS One. 2014 Jul 31;9(7):e103512. doi: 10.1371/journal.pone.0103512. eCollection 2014.


Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group.

N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1.


Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives.

De Boer R, Beith J, Chirgwin J, Chua S, Colosimo M, Francis P, Green M, Pittman K, White M, Wilcken N, Zdenkowski N, Bell R.

Asia Pac J Clin Oncol. 2014 Jun;10 Suppl S4:15-25. doi: 10.1111/ajco.12207. Review.


Systemic treatment of HER2-positive metastatic breast cancer: a systematic review.

Wilcken N, Zdenkowski N, White M, Snyder R, Pittman K, Mainwaring P, Green M, Francis P, De Boer R, Colosimo M, Chua S, Chirgwin J, Beith J, Bell R.

Asia Pac J Clin Oncol. 2014 Jun;10 Suppl S4:1-14. doi: 10.1111/ajco.12206. Review.


Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).

McCarthy N, Boyle F, Zdenkowski N, Bull J, Leong E, Simpson A, Kannourakis G, Francis PA, Chirgwin J, Abdi E, Gebski V, Veillard AS, Zannino D, Wilcken N, Reaby L, Lindsay DF, Badger HD, Forbes JF; Australia and New Zealand Breast Cancer Trials Group.

Breast. 2014 Apr;23(2):142-51. doi: 10.1016/j.breast.2013.12.001. Epub 2014 Jan 3.


Efficacy and cost-effectiveness of an outcall program to reduce carer burden and depression among carers of cancer patients [PROTECT]: rationale and design of a randomized controlled trial.

Livingston PM, Osborne RH, Botti M, Mihalopoulos C, McGuigan S, Heckel L, Gunn K, Chirgwin J, Ashley DM, Williams M.

BMC Health Serv Res. 2014 Jan 6;14:5. doi: 10.1186/1472-6963-14-5.


Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.


Aromatase inhibitors associated with knee subchondral bone expansion without cartilage loss.

Davis SR, Bell RJ, Wang Y, Hanna F, Davies-Tuck M, Bell R, Chirgwin J, Cicuttini F.

Climacteric. 2013 Dec;16(6):632-8. doi: 10.3109/13697137.2012.746656. Epub 2012 Dec 10.


Supplemental Content

Loading ...
Support Center